ClinicalTrials.gg
TerminatedNCT02368691Updated Nov 18, 2020Results posted

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

A Phase 2 interventional study of GTx-024 in Triple Negative Breast Cancer, sponsored by GTx. Terminated at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by GTx · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of Efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Enrollment
401st of 605
32 · median 52
Started
2015
with 36 others
Phase 2
191 of 645
45 open now
Registered
111th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 401st largest by enrollment of the 605 interventional ones that give a count, is one of 37 that started in 2015, is one of 191 in phase 2, and was the 111th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if GTx-024 is effective and safe in the treatment of patients with advanced, androgen receptor positive triple negative breast cancer (AR+ TNBC).

03

Conditions studied

  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to give voluntary, written and signed,
  • Women ≥ 18 years of age
  • Women with TNBC who have received at least one but no more than two prior chemotherapy regimens for TNBC
  • Confirmation of AR+ (defined as ≥ 10% nuclear AR staining by immunohistochemistry [IHC]) TNBC in either the primary or lesion, assessed during the screening period by a local laboratory or by medical history
  • TNBC confirmed by medical history as: human epidermal growth factor receptor 2 []-negative (confirmed by IHC 0, 1+ regardless of fluorescence in situ hybridization [FISH] ratio; IHC 2+ with FISH ratio lower than 2.0 or HER2 gene copy less than 6.0; FISH ratio of 0, indicating gene deletion, when positive and negative in situ hybridization [ISH] controls are present); estrogen receptor (ER) negative (confirmed as ER expression less than or equal to 1% positive tumor nuclei); progesterone receptor negative (confirmed as progesterone receptor expression less than or equal to 1% positive tumor nuclei)
  • Availability of paraffin embedded or formalin fixed tumor tissue; OR, a minimum of 10 and up to 20 slides of archived tumor tissue for central laboratory confirmation of AR status and molecular subtyping. Metastatic tumor tissue is preferred when possible
  • Subjects must have either or bone-only non-measurable disease, evaluable according to 1.1
  • Subjects with bone metastases should be treated with intravenous bisphosphonates or subcutaneous denosumab (or investigator preferred standard of care) prior to and during the trial, unless there is a or subject intolerance to these therapies
  • (ECOG) performance status 0 or 1 at the time of screening and enrollment
  • Negative pregnancy test in women of (premenopausal or less than 12 months of amenorrhea , and who have not undergone surgical sterilization), no more than 7 days before the first dose of study treatment
  • For women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of during and for at least 6 months after completion of study treatment; OR, a fertile male partner willing and able to use effective non-hormonal of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilization) during and for at least 6 months after completion of study treatment
  • Adequate organ function as shown by:

    • ≥ 1,000 cells/mm3
    • count ≥ 100,000 cells/mm3
    • ≥ 9 g/dL
    • Serum (AST) and alanine aminotransferase (ALT) ≤ 2.5 (ULN) (or ≤ 5 if hepatic metastases are present)
    • Total serum ≤ 2.0 × ULN (unless the subject has documented Gilbert Syndrome)
    • Alkaline phosphatase levels ≤ 2.5 × ULN (≤ 5 × ULN in subjects with liver metastasis)
    • Serum creatinine \< 2.0 mg/dL or 177 μmol/L
    • (INR), activated partial thromboplastin time (aPTT), or partial thromboplastin time (PTT) \< 1.5 × ULN (unless on anticoagulant treatment at screening)
  • Able to swallow capsules
  • Any toxicity from prior chemotherapy has resolved or Grade 1 (, Version 4.0)

Exclusion criteria

Exclusion Criteria:

  • \< 4 months;
  • Subjects with radiographic evidence of central nervous system (CNS) as assessed by computerized tomography (CT) or magnetic resonance imaging (MRI) that are not well controlled (symptomatic or requiring control with continuous therapy [e.g., dexamethasone]). Note: Subjects with are permitted to participate in the study if the CNS metastases are medically well controlled prior to screening (as assessed by the Investigator) after receiving local therapy (irradiation, surgery, etc.)
  • Radiotherapy within 14 days prior to first dose of study treatment
  • Have, in the judgment of the Investigator, a concurrent illness or psychological, familial, sociological, geographical, or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
  • Positive virus (HBV) and/or virus (HCV) infection at screening
  • Positive (HIV) infection at screening
  • Prior treatment with any anti-androgens, including but not limited to, enzalutamide and bicalutamide
  • Major surgery within 28 days of the first dose of study treatment
  • Be currently taking or have previously taken testosterone, methyltestosterone, oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), or anti-androgens
  • Treatment with any of the following hormone replacement therapies, unless discontinued at least 14 days prior to the first dose of study treatment:

    • Estrogens
    • Megesterol acetate
  • Treatment with any agent within 28 days before the first dose of study treatment
  • Another active cancer (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed as long as there is no active disease within the prior 5 years
  • Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator, such as but not limited to:

    • Myocardial infarction or arterial thromboembolic events within 6 months prior to baseline or severe or unstable angina, (NYHA) Class III or IV disease, or a (corrected according to Bazett's formula) interval > 470 msec; serious uncontrolled cardiac arrhythmia grade II or higher according to NYHA; uncontrolled hypertension (systolic > 150 and/or diastolic > 100 mm Hg)
    • Acute and chronic active infectious disorders and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy
    • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
  • Current treatment with intravenous bisphosphonate or denosumab with elevated serum calcium corrected for albumin or ionized calcium levels outside institutional normal limits at screening
  • History of non-compliance to medical regimens
  • Subjects unwilling to or unable to comply with the protocol procedures as assessed by the Investigator
  • Concurrent participation in another therapeutic clinical trial
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    GTx-024

    GTx-024 capsules, 18 mg PO once-daily for up to 12 months

    Drug: GTx-024

Interventions

  • GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg

    Also known as: Enobosarm, Ostarine, S-22

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects

    To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST) as assessed by CT or MRI in subjects with centrally confirmed AR+ status. Clinical Benefit Rate=CR+PR+SD. Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, \<30% decrease in sum of the longest diameter of target lesions.

    Time frame: Sixteen (16) weeks

Secondary outcomes

  1. Clinical Benefit Rate, in Full Analysis Set

    To estimate the clinical benefit rate in all subjects who receive at least one dose of study medication (full analysis set), regardless of central confirmation of AR status.

    Time frame: Sixteen (16) weeks

  2. Best Overall Response

    To assess best overall response as measured by RECIST 1.1 from the start of study treatment until the end of treatment taking into account any requirement for confirmation. Best overall response is reported as the best response (CR, PR or SD) by CT or MRI up through 11 months of treatment, median duration of treatment 1.9 months.

    Time frame: From treatment initiation to end of treatment (up through 11 months of treatment, median duration of treatment 1.9 months).

  3. Progression Free Survival

    To assess progression free survival (PFS) defined as the time elapsed between initiation of treatment and tumor progression as measured by RECIST 1.1 or death.

    Time frame: From treatment initiation to tumor progression or death. PFS was assessed up to 11 months of treatment; median duration of treatment, 1.9 months

  4. Time-to-progression

    To assess time to progression defined as time elapsed between treatment initiation and tumor progression as measured by RECIST 1.1 or death due to disease progression.

    Time frame: From treatment initiation to tumor progression or death. Time to progression was assessed up to 11 months of treatment; median duration of treatment, 1.9 months

  5. Duration of Response

    To assess the duration of response defined as the time from documentation of tumor response to disease progression or death

    Time frame: From time of documented tumor response to tumor progression or death. Duration of response was assessed through 11 months; median treatment duration, 1.9 months

  6. Objective Response Rate

    To estimate the objective response rate (defined as complete response or partial response) according to RECIST 1.1.

    Time frame: Sixteen (16) weeks

Other outcomes

  1. Number of Participants With Adverse Events

    To describe the safety profile in subjects with TNBC and centrally confirmed AR+ as well as in all subjects enrolled and treated.

    Time frame: Up to twelve (12) months

07

Results

Posted Oct 30, 2020
Limitations and caveats
Early termination due to lack of efficacy and limited data reported.

Participant flow

Up to 55 patients were planned for enrollment

Participant flow — Overall Study
MilestoneGTx-024
Started32
Completed0
Not completed32
Withdrew: Death13
Withdrew: Lack of efficacy15
Withdrew: Physician decision4

Outcome measures

PrimaryClinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects

To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST) as assessed by CT or MRI in subjects with centrally confirmed AR+ status. Clinical Benefit Rate=CR+PR+SD. Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, \<30% decrease in sum of the longest diameter of target lesions.

Time frame:
Sixteen (16) weeks
Reported as:
Count of participants · Participants
Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects
ParticipantsGTx-024
Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects1
SecondaryClinical Benefit Rate, in Full Analysis Set

To estimate the clinical benefit rate in all subjects who receive at least one dose of study medication (full analysis set), regardless of central confirmation of AR status.

Time frame:
Sixteen (16) weeks
Reported as:
Number · participants
Clinical Benefit Rate, in Full Analysis Set
participantsGTx-024
Clinical Benefit Rate, in Full Analysis Set2
SecondaryBest Overall Response

To assess best overall response as measured by RECIST 1.1 from the start of study treatment until the end of treatment taking into account any requirement for confirmation. Best overall response is reported as the best response (CR, PR or SD) by CT or MRI up through 11 months of treatment, median duration of treatment 1.9 months.

Time frame:
From treatment initiation to end of treatment (up through 11 months of treatment, median duration of treatment 1.9 months).
Reported as:
Number · participants
Best Overall Response
participantsGTx-024
Best Overall Response6
SecondaryProgression Free Survival

To assess progression free survival (PFS) defined as the time elapsed between initiation of treatment and tumor progression as measured by RECIST 1.1 or death.

Time frame:
From treatment initiation to tumor progression or death. PFS was assessed up to 11 months of treatment; median duration of treatment, 1.9 months
Reported as:
Number · months
Progression Free Survival
monthsGTx-024
Progression Free Survival1.9 (1.7 to 2.3)
SecondaryTime-to-progression

To assess time to progression defined as time elapsed between treatment initiation and tumor progression as measured by RECIST 1.1 or death due to disease progression.

Time frame:
From treatment initiation to tumor progression or death. Time to progression was assessed up to 11 months of treatment; median duration of treatment, 1.9 months
Reported as:
Number · months
Time-to-progression
monthsGTx-024
Time-to-progression1.9 (1.7 to 2.0)
SecondaryDuration of Response

To assess the duration of response defined as the time from documentation of tumor response to disease progression or death

Time frame:
From time of documented tumor response to tumor progression or death. Duration of response was assessed through 11 months; median treatment duration, 1.9 months
Reported as:
Median · months
Duration of Response
monthsGTx-024
Duration of Response1.9 (0.1 to 11)
SecondaryObjective Response Rate

To estimate the objective response rate (defined as complete response or partial response) according to RECIST 1.1.

Time frame:
Sixteen (16) weeks
Reported as:
Number · participants
Objective Response Rate
participantsGTx-024
Objective Response Rate0
Other pre-specifiedNumber of Participants With Adverse Events

To describe the safety profile in subjects with TNBC and centrally confirmed AR+ as well as in all subjects enrolled and treated.

Time frame:
Up to twelve (12) months
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsGTx-024
Number of Participants With Adverse Events28

Adverse events

Collected over one year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GTx-02413/32 (40.6%)5/32 (15.6%)28/32 (87.5%)
Most frequent serious events
Most frequent serious events
EventGTx-024
CHFCardiac disorders1/32
pleural effusionCardiac disorders1/32
pulmonary embolismVascular disorders1/32
tumor flareNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/32
UTIRenal and urinary disorders1/32
dehydrationMetabolism and nutrition disorders1/32
constipationGastrointestinal disorders1/32
rib fractureMusculoskeletal and connective tissue disorders1/32
Most frequent other events
Most frequent other events
EventGTx-024
investigationsInvestigations13/32
GIGastrointestinal disorders8/32
metabolismMetabolism and nutrition disorders8/32
blood disorderBlood and lymphatic system disorders4/32
nervous systemNervous system disorders3/32
rashSkin and subcutaneous tissue disorders3/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)GTx-024
Median65 (35 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)GTx-024
Female32
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GTx-024
Caucasian27
Region of Enrollment
Region of Enrollment(Participants)GTx-024
United States32
AR status-positive
AR status-positive(participants)GTx-024
Number18
08

Study locations

7 sites
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Lakeland Regional Health Care/Cancer Center
    Lakeland, Florida 33805, United States
  • University of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • The West Clinic, PC
    Memphis, Tennessee 38120, United States
  • US Oncology / Texas Oncology, P.A.
    Houston, Texas 77024, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Sep 2017, 27 months.

Results were first posted in Oct 2020, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2015
First posted
Feb 23, 2015
StartActual
Jun 2015
Primary completionActual
Sep 22, 2017
CompletionActual
Sep 22, 2017
Results first posted
Oct 30, 2020
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02368691
Lead sponsor
GTx
Responsible party
Sponsor
First posted
Feb 23, 2015
Start date
Jun 2015
Primary completion
Sep 22, 2017
Completion
Sep 22, 2017
Results posted
Oct 30, 2020
Last update
Nov 18, 2020

Study contacts

Hope S Rugo, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion